Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

ViaCyte
3550 General Atomics Court
San Diego, CA 92121
Phone: 858-455-3708

ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

Key Contact
Name
Paul Laikind
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
07/10/13 $10,600,000 Series C-1 Asset Management Ventures
Johnson & Johnson Innovation
Sanderling Ventures
undisclosed
08/08/14 $5,400,000 Series C-1
08/25/14 $20,000,000 Janssen Research & Development
undisclosed
11/30/18 $80,000,000 Series D Bain Capital
RA Capital Management
Sanderling Ventures
TPG
undisclosed